Abstract
O. Hergesell and E. Ritz 864 Table 1 . Parameters of calcium metabolism and renal function at eight males and five females, median age 61 years, range the end of the run-in period, i.e. off phosphate binders 42-74. The underlying renal diseases were: diabetic nephropathy (n=6), IgA-glomerulonephritis (n=3), polycystic kidney disease (n=1), reflux nephropathy (n=1), membran-
Median Range
Normal range ous glomerulonephritis (n=1) and chronic glomerulonephritis, not biopsy proven (n=1). Besides the study Plasma-creatinine decrease of plasma-Pi in the 13 patients at days 14 and
This was verified by three measurements in the 2 weeks prior 28. Figure 2 gives the per cent decrease of urinary-Pi to the study. Median urinary phosphate excretion was 23.5 mmol/day, range 21-34 mmol/day; median intraindivid-excretion rate in the individual 13 patients at days 14 ual VC 8.6%, 4.5-17.8%. After the run-in period without and 28. The median per cent decrease between the phosphate binders, patients were subsequently given a con-average plasma-Pi concentration in the run-in period stant dose of 3×2.5 g stabilized polynuclear iron hydroxide and the treatment period was 20% (range 7.2-41%).
(courtesy Vifor Company, St. Gallen, Switzerland ) provided The respective figures for urinary-Pi excretion were as a powder in preweighed sachets. The material was sus-37% (range 9.6-56.6%). With one exception, potenpended in water and ingested together with meals. Plasma-tially caused by non-compliance, the effect persisted
Pi and urinary-Pi in 24-h urine collections were measured throughout the 28-day observation period. Table 2 once weekly for the total duration of 4 weeks study.
gives the information on plasma-Pi concentration and urinary-Pi excretion at the end of the the run-in phase Measurements and during treatment phase on day 14 and 28. The values of plasma-Pi on day 14 and 28, respectively did All measurements were performed in a central laboratory not differ more than by 6.7% (range 4-14%) and under blinded conditions. The i-PTH petide in plasma was urinary-Pi by 11% (range 2-18%).
measured by two-site immunoradiometric assay [14] . 1,25(OH ) 2 D was quantitated by radioimmunoassay [15] and 25(OH )D by protein binding assay [16 ] . Plasma-Pi and Ancillary measurements urinary-Pi and urinary-Pi were measured using autoanalyser techniques. The same was true for creatinine, urine- Table 3 gives the changes of Ca, i-PTH, 1,25(OH ) 2 D, creatinine, alkaline phosphatase, total protein, and calcium. 25(OH )D, serum iron and ferritin concentrations at Determination of serum-iron and serum-ferritin was carried the end of the run-in and the end of the treatment out with standard methods. phase (day 28) respectively.
Statistics
Side effects
All patients reported that the frequency of defecation
The predetermined primary end-points were the per cent decrease of (i) fasting plasma-Pi concentration and (ii) of had increased (from an average of one per day, range daily urinary-Pi excretion. These differences were evaluated 0-3, in the run-in phase to two per day, range 1-4). by Wilcoxon test for paired differences. All other measure-Faeces turned black, reflecting the increased iron conments were regarded as descriptive and exploratory. Data tent. The average volume of water consumed by dissolwhich are not normally distributed are given as median ving the contents of the sachets was 75 ml per sachet and range.
(range 50-100 ml ). Patients did not report any side effects, apart from increased frequency of defecation.
Results

Discussion
Baseline data Table 1 gives the relevant parameters of calcium meta-The results of this uncontrolled open pilot study are encouraging. It was designed to evaluate efficacy and bolism and renal function at the beginning of the study.
Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients 865 Fig. 1 . Per cent decrease of plasma phosphate in 13 patients with stable preterminal renal failure at days 14 and 28, respectively. tolerability of a novel phosphate binder. The results on pilot studies in animals failed to produce normophosphataemia in most patients. Nevertheless, the average document a consistent decrease of plasma-Pi and a reduction of urinary-Pi in all of the 13 hyperphosphata-37% decrease of urinary-Pi excretion indicates that a substantial amount of phosphate had been bound in emic patients with stable preterminal renal failure, at least initially. The delayed increase in one of 13 patients the intestine. Presumably a somewhat higher dose is required to achieve normophosphataemia. raises the suspicion of non-compliance. The tolerability of the compound was excellent (this was confirmed by
In principle this insoluble polynuclear iron(III )-hydroxide acts by iron-phosphate complex formation the investigators who also ingested the compound over the same period). Nevertheless modifications of the [13] . Further product information is given in the patent application text [13] . preparation to further reduce the amount of water required for suspending the compound are desirable.
In brief, the in vitro binding capacity is 0.0063 mmolP/mg Fe at a bath concentration of The dose of 3×2.5 g/day that we had selected based Table 3 . 1,25(OH ) 2 -D, 25(OH )D, i-PTH, plasma-calcium, serum-ferritin and serum-iron values at the end of the run-in phase and at days 14 and 28 of the study
